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Sixty small cell tumors of bone and adjacent soft tissue were studied in an attempt
to define the incidence of immunohistochemically detectable p53 protein and cor-
relate these findings with the results of proliferating cell nuclear antigen (PCNA)
immunohistochemical staining and mitotic counts. All of the lesions had been for-
malin-fixed and paraffin-embedded; half were subjected to decalcification prior to
processing. The study population included 12 Ewing’s sarcomas of bone, 3 atypical
Ewing’s sarcomas of bone, 3 primitive neuroectodermal tumors of bone, 11 Askin
tumors of the thoracopulmonary region, 11 small cell osteosarcomas of bone, 10
mesenchymal chondrosarcomas of bone, and 10 malignant lymphomas involving
bone. The patients ranged in age at the time of presentation from 17 to 67 years.
Overall, the incidence of p53 positivity was extremely low in these lesions, irre-
spective of tumor type. Positive nuclear staining with an antibody to p53 was found
in none of the 12 Ewing’s sarcomas, none of the 3 atypical Ewing’s sarcomas, none
of the 3 primitive neuroectodermal tumors of bone, 1 of the 11 Askin tumors of the
thoracopulmonary region (1.5% of tumor cells positive), 1 of the 11 small cell
osteosarcomas (2% of tumor cells positive), 1 of the 10 mesenchymal chondrosar-
comas of bone (7% of tumor cells positive), and 2 of the 10 malignant lymphomas
involving bone (0.5% and 1% of tumor cells positive, respectively). The majority of
tumors showed PCNA positivity within the tumor cells, although the incidence of
PCNA positivity within the histologic types varied greatly; in general, the higher
PCNA counts corresponded to higher mitotic counts within the individual lesions.
The present study did not demonstrate any correlation between mutant p53 accu-
mulation detected by immunohistochemistry and tumor type, and so it is unlikely
that p53 positivity will prove to be of great use in the differential diagnosis of these
lesions. A correlation between p53 positivity and PCNA staining or mitotic activity
was not apparent. Int J Surg Pathol 2(4):259-268, 1995
Key words: Ewing’s sarcoma, Askin tumor, neuroectodermal tumor, mesenchymal
chondrosarcoma, small cell osteosarcoma, lymphoma, p53, PCNA.
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The introduction of new technologies into the
practice of diagnostic pathology often invites a re-
examination of what previously were challenging
diagnostic problems in the hope of better defining
diagnostic or prognostic criteria. The potential diag-
nostic dilemma presented by the &dquo;small round cell
tumor of bone&dquo; is a classic example of this problem
that is faced by the surgical pathologist in routine
practice. Only recently, with the introduction of
newer investigative modalities, such as antibodies
directed against the HBA71 antigen and fluorescent
in situ hybridization for detection of the cytogenetic
abnormality t(11;22) for the prospective identifica-
tion of the Ewing’s sarcoma or primitive neuroecto-
dermal tumor family lesions (often taken to include
typical and atypical Ewing’s sarcoma, the Askin
tumor of the thoracopulmonary region, and primi-
tive neuroectodermal tumors of bone and soft tissue),
have great strides been made in addressing this vex-
ing problem for the diagnostic pathologist. 1,2
The present study was undertaken to determine
the incidence of nuclear p53 protein positivity by
immunohistochemical means in a large group of
small cell bone lesions and to explore the potential
application of these findings to the differential
diagnosis and prognosis of these lesions. At the
same time, proliferating cell nuclear antigen
(PCNA) immunostaining of the lesions and calcu-
lation of the mitotic counts were carried out for
correlation with the p53 results. In view of the
ready availability of immunohistochemical tech-
niques to the diagnostic surgical pathologist (and,
conversely, the difficulty at present in carrying out
sophisticated molecular studies in many hospitals),
immunohistochemical staining for the presence of
an antigen such as p53 might provide valuable
prognostic, diagnostic, or therapeutic information,
which may serve as a clinical assay for use in the
general pathologist’s practice.
Materials and Methods
Sixty biopsies of small cell lesions of bone and
adjacent soft tissue were drawn from the consulta-
tion files of the Armed Forces Institute of Pathology
and the Rhode Island Hospital. Twenty-nine of the
cases were the subject, in part, of an earlier report
of the immunohistochemical features of small
round cell tumors of bone.3 The remaining cases
were collected both prospectively and from the
archives of the Armed Forces Institute of Pathology
and the Rhode Island Hospital; the oldest cases
(embedded in paraffin) dated back to the 1960s.
In each instance, hematoxylin and eosin-stained
sections were available for study; in many cases,
periodic acid-Schiff-stained sections (both with
and without diastase pretreatment) were avail-
able as well. Some of the lesions had been studied
ultrastructurally, but this was not the focus of the
present report and so was not uniformly employed
in all of the study cases. The final diagnosis in each
of the 60 study cases was based on the light micro-
scopic features of the individual lesions, employing
criteria that have been previously reported.’
The study population consisted of 12 classic
osseous Ewing’s sarcomas (Fig. 1), 3 atypical osseous
Ewing’s sarcomas, 3 primitive neuroectodermal
tumors of bone (Fig. 2), 11 Askin tumors of the tho-
racopulmonary region (Fig. 3), 11 small cell osteosar-
comas of bone (Fig. 4), 10 mesenchymal chondrosar-
comas of bone (Fig. 5), and 10 malignant lymphomas
involving bone. The patients ranged in age at the time
of presentation from 17 to 67 years.
All tissues studied by immunohistochemistry had
been formalin-fixed and paraffin-embedded;
approximately half had been subjected to decalcifi-
cation prior to processing (by a variety of methods).
Five of the Ewing’s sarcomas, 5 of the mesenchymal
chondrosarcomas, 4 of the Askin tumors, 3 of the
small cell osteosarcomas, and 4 of the lymphomas
consisted of lesions in which both decalcified and
undecalcified tumor blocks were available; in these
21 tumors, a comparison between decalcified and
undecalcified specimens with regard to differences
in the incidence of either p53 or PCNA immuno-
staining was performed. The antibody to p53 was a
polyclonal antibody to mutant type p53 (CM1,
Novocastra Laboratories, Newcastle upon Tyne;
diluted 1:400), while the antibody to PCNA was a
Fig. 1. The classic Ewing’s sarcoma is marked by a
sheetlike proliferation of relatively uniform small round
cells, often with clear to finely vacuolated cytoplasm and
small nuclear chromocenters (hematoxylin and eosin,
original magnification X220).
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Fig. 2. Peripheral neuroectodermal tumor of bone was
defined by light microscopy as a lesion composed of
sheets of cells similar to those of Ewing’s sarcoma but
with the added architectural requirement that more
than half of the tissue showed evidence of pseudorosette
formation (formation of true rosettes was not noted)
(hematoxylin and eosin, original magnification X 120).
monoclonal preparation (Dako Corp., Carpenteria,
CA; diluted 1:500). Sections were developed using a
modified avidin-biotin-peroxidase complex tech-
nique.’ Controls used within each run included pos-
itive and negative control tissues; formalin-fixed,
paraffin-embedded colonic adenocarcinoma served
as the positive control for p53 staining (over 90% of
the tumor cells were consistently positive), while
negative controls consisted of a section of each
tumor being studied with substitution of nonim-
mune rabbit serum for the primary antibody.
Antigen retrieval was carried out by heating
Fig. 3. The component cells of the Askin tumors of the
thoracopulmonary region resembled Ewing’s sarcoma
cells in many lesions, with a somewhat greater tendency
toward elongation of the nuclei in some areas (hema-
toxylin and eosin, original magnification X220).
Fig. 4. The small cell osteosarcomas were characterized
by a proliferation of hyperchromatic round to oval
tumor cells that often exhibited a greater degree of
nuclear pleomorphism than was seen in the classic
Ewing’s sarcomas; formation of osteoid by the tumor
cells (as seen here) was found only focally (hematoxylin
and eosin, original magnification X220).
deparaffinized tissue sections for 10 minutes in a
solution of citrate buffer. A microwave oven was
employed as a source of heating for this process.
In each case, 200 tumor cells were counted, and
the presence or absence of positive nuclear staining
with antibody to p53 and to PCNA was noted. In
cases in which a variable degree of staining was
appreciated within the specimen, counting was
done in the most intensely stained zone. The per-
centage of positive cells was recorded in each
Fig. 5. A juxtaposition of two components (islands of
cartilage embedded in a sea of hyperchromatic small
round to oval cells) typified the mesenchymal chon-
drosarcomas of bone (hematoxylin and eosin, original
magnification X220).
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instance. Within the same region, the number of
mitotic figures was counted in 20 high-power fields
(HPF) (Olympus microscope, 40 X objective and lOX
ocular lens, field area 0.159 mm2) and recorded as
mitoses per 10 HPF.
Results
Positive nuclear staining with an antibody to p53
was found in none of the 12 Ewing’s sarcomas,
none of the 3 atypical Ewing’s sarcomas, none of
the 3 primitive neuroectodermal tumors of bone, 1
of the 11 Askin tumors of the thoracopulmonary
region ( 1.5 % of tumor cells positive), 1 of the 11 1
small cell osteosarcomas (2% of tumor cells posi-
tive) (Fig. 6), 1 of the 10 mesenchymal chon-
drosarcomas of bone (7% of tumor cells positive)
(Fig. 7), and 2 of the 10 malignant lymphomas
involving bone (0.5% and 1 % of tumor cells posi-
tive, respectively).
Some degree of PCNA positivity was found in the
majority of tumors studied, irrespective of the his-
tologic subtype; however, within each histologic
type, a wide variation in the percentage of positive
cells was seen. Specifically, 10 of 12 Ewing’s sarco-
mas were PCNA positive (range, 1 % to 92% of
tumor cells positive, mean 29%) (Fig. 8); 2 of 3
atypical Ewing’s sarcomas were PCNA positive (5%
and 94% of tumor cells positive, respectively); 2 of
3 primitive neuroectodermal tumors of bone were
PCNA positive ( 1 % and 13% of tumor cells posi-
tive, respectively); 11 of 11 Askin tumors of the
thoracopulmonary region were PCNA positive
(range, 12% to 94% of tumor cells positive, mean
43%); 10 of 11 1 small cell osteosarcomas were
PCNA positive (range, 1 % to 88% of tumor cells
Fig. 6. Immunostaining of this small cell osteosarcoma
with antibody to p53 yielded only rare positive cells
(center of figure) (antibody to p53, hematoxylin coun-
terstain, original magnification X220).
Fig. 7. Immunostaining of this malignant lymphoma of
bone with antibody to p53 yielded only rare positive
tumor cells (antibody to p53, hematoxylin counterstain,
original magnification X220).
positive, mean 34%); 9 of 10 mesenchymal chon-
drosarcomas of bone were PCNA positive (range,
2% to 66% of tumor cells positive, mean 19%);
and 9 of 10 malignant lymphomas involving bone
were PCNA positive (range, 1 % to 87% of tumor
cells positive, mean 41 % ) .
The highly variable degree of PCNA positivity
within the individual tumor types corresponded to
the variable mitotic count within the lesional types
studied. The Ewing’s sarcomas of bone had from 1
to 18 mitoses/ 10 HPF; the atypical Ewing’s sarco-
mas had from 2 to 11 mitoses/ 10 HPF; the primitive
neuroectodermal tumors had from 1 to 7 mitoses/ 10
Fig. 8. Immunostaining with antibody to proliferating
cell nuclear antigen (PCNA) yielded some degree of pos-
itive nuclear staining in the majority of the tumors stud-
ied, although the proportion of positive cells varied
greatly from one lesion to another; shown here is a clas-
sic Ewing’s sarcoma of bone in which approximately
35% of the tumor cells were PCNA positive (antibody to
PCNA, original magnification X220).
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HPF; the Askin tumors of the thoracopulmonary
region had from 2 to 28 mitoses/ 10 HPF; the small
cell osteosarcomas had from 3 to 38 mitoses/10
HPF; the mesenchymal chondrosarcomas of bone
had from 1 to 9 mitoses/ 10 HPF; and the malignant
lymphomas involving bone had from 4 to 18
mitoses/ 10 HPF.
A direct correspondence between an increasing
level of PCNA positivity and the mitotic count was
noted in this study; this correspondence (that is, the
finding of a high percentage of PCNA positive tumor
cells in a given tumor usually predicted a higher
mitotic rate within that lesion) was found irrespective
of the histologic group of tumor studied.
No relationship was seen between the rare p53
positive tumors in each group and either the per-
centage of PCNA positive cells or the mitotic
counts; that is, p53 positivity did not correspond
either to a strikingly high or strikingly low rate of
PCNA positivity or mitotic activity.
Previous decalcification did not produce an
appreciable effect on the incidence or quantity of
PCNA staining. The impact of prior decalcification
on p53 immunostaining was more difficult to
judge, in view of the extremely low incidence of
p53 staining found in the study population overall.
Discussion
The present study found a consistently low inci-
dence of positive nuclear staining of tumor cells with
antibody to mutant p53 in a variety of small cell
lesions of bone, including the Ewing’s/primitive neu-
roectodermal family of tumors, small cell osteosar-
coma, and mesenchymal chondrosarcoma. To place
these observations in context, Table 1 includes a tab-
ulation of selected reports on the incidence of positive
immunohistochemical staining of tumor cell nuclei in
a variety of musculoskeletal tumors as well as the
findings of the present investigation.5-’ 3
It has been established that, among the tumor
suppressor genes that have been characterized to
date, abnormalities involving the p53 gene (also
known as the TP53 gene) are extremely common in
a host of different human tumor types. 14-30 The nor-
mal p53 gene (located on the short arm of chromo-
some 17) plays a role in the regulation of a cell’s
entry into the S phase, producing a nuclear phos-
phoprotein (the wild-type p53 protein) that acts to
interfere with the transcription of DNA and so
impedes cell proliferation. In experimental systems,
the wild-type p53 protein has been shown to slow
or even inhibit altogether cellular transformation
by oncogenes. 18 Inactivation of the p53 gene may
result either from deletion of the gene or from its
mutation. The precise mechanisms are extremely
complex and continue to be incompletely under-
stood ; however, it is known that a variety of differ-
ent mutations may affect the p53 gene in different
tumor types. 17, &dquo; The phenomenon of p53 alteration
has been best studied in large intestinal adenocarci-
nomas, in which a majority of tumors exhibit a loss
of one p53 allele via mutation and a loss of the
other p 5 3 allele through deletion. 17,18
Table 1. Frequency of p53 Positivity by Immunohistochemistry in Musculoskeletal Tumors
PNET, peripheral primitive neuroectodermal tumor; rare, reported in less than 10% of tumors of this type;
uncommon, reported in 10% to 30% of tumors of this type; common, reported in more than 30% of tumors
of this type.
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With regard to the present study, the failure of an
appreciable number of the small cell osteosarcomas
to stain with antibody to the p53 protein is some-
what at odds with the expected results as might have
been predicted by the reports describing the finding
of relatively frequent mutations of the p53 gene in
osteosarcomas with accompanying p53 protein accu-
mulation by immunohistochemistry, as noted in
Table 1.6,’ This may simply reflect the occasional lack
of close correlation between these two parameters,
as has been hinted at in other tumor types. It has
been noted in some tumors, including some
hematopoietic and hepatic neoplasms, that the inci-
dence of p53 protein overexpression may exceed the
incidence of p53 gene mutations.31-33 Such an appar-
ent discrepancy may indicate accumulation of a
nonmutated p53 protein (particularly likely when
the antibody employed recognizes epitopes on both
wild-type and mutant p53 protein), or even cross-
reactivity of the antibody with other nuclear compo-
nents than the p53 protein itself.
Moreover, despite a finding of p53 mutation (as
detected by polymerase chain reaction) in some
sarcomas, the corresponding production of a pro-
tein detectable by immunohistochemistry is not
always observed.’ Such an occurrence may reflect
the presence of a p53 gene mutation that produces
not a missense mutation, which typically yields a
detectable increase in nuclear p53 protein by
immunohistochemistry, but that results in a non-
sense mutation or even a gross deletion of the gene.
In addition, failure of immunohistochemistry to
detect p53 protein accumulation may correspond to
technical inadequacies within the tissue, such as
over- or underfixation. Others have observed that,
while p53 mutations are usually not found in pri-
mary tumor samples of Ewing’s sarcoma, cell lines
derived from those same tumors often will show
evidence of p53 gene mutation, reflecting, perhaps,
some survival advantage conferred in the culture
environment by the mutation.34.35
Such observations raise questions about the reli-
ability of p53 immunostaining as a marker for
detectable mutations of the p53 gene in at least
some mesenchymal tumors. It may prove to be that
(in contrast to many carcinomas) some sarcomas
either do not show frequent p53 gene mutations, or
these mutations may fail to result in the production
of a protein product not detectable by presently
employed techniques. To date, mutations of the
p53 gene have been identified less frequently in
sarcomas than in epithelial malignancies; among
the two mesenchymal tumor types that do exhibit
an appreciable frequency of p53 mutation by gene
sequencing are rhabdomyosarcomas and osteosar-
comas.19.36.37 Apparent overexpression of the p53
protein product (manifested as positive immuno-
histochemical staining) has been reported in an
admixture of non-neoplastic, benign, and malig-
nant soft tissue lesions, suggesting that further
studies are required to explain these findings.9
The present investigation employed a widely
used antibody directed toward mutant p53 protein,
the CM1 polyclonal antibody. As in all immunohis-
tochemical investigations, our study is subject to
variations that may have been produced by a num-
ber of potential variables, including type of tissue
fixative employed, length of fixative exposure, and
varying sensitivities and specificities among the
various commercially available antisera. The poten-
tial influence of these and other variables must be
borne in mind when interpreting the results of an
immunohistochemical study such as ours. Antigen
retrieval was employed in an attempt at minimizing
the impact of these potentially confounding factors.
This study of paraffin-embedded tissues did not
permit either comparison of frozen with fixed tissue
sections or of decalcified with undecalcified tissues
within the same tumor in each instance. Five of the
Ewing’s sarcomas, 5 of the mesenchymal chon-
drosarcomas, 4 of the Askin tumors, 3 of the small
cell osteosarcomas, and 4 of the lymphomas con-
sisted of lesions in which a portion of the tumor
had been decalcified and a portion had not. In these
21 tumors, a comparison between decalcified and
undecalcified specimens did not yield an apprecia-
ble difference in the incidence of either p53 or
PCNA immunostaining, suggesting that decalcifica-
tion does not appear to have an appreciable effect
on these results.
Although an estimation of a tumor’s mitotic
activity has classically been cited as an index of that
tumor’s proliferative activity (and hence, presum-
ably, provides some insight into the degree of
aggressiveness of that tumor as an independent his-
tologic parameter), it has been suggested by some
observers that this is not necessarily always the
case. Mitosis counting has been criticized as lacking
in reproducibility among different (and even the
same) observers, subject to variation as a function
of tissue processing, and simply lacking significance
in strict follow-up studies of certain tumor
types6
In light of the above considerations, attempts
have been made at identifying alternate methods of
assessing proliferative activity, methods that would
prove to be both reproducible and statistically sig-
nificant. These alternative approaches may be
divided into two broad groups: first, the more tech-
nically difficult or expensive methods, which
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include the use of flow cytometry, tritiated thymi-
dine, and bromodeoxyuridine; and second, the less
involved/or expensive methods, including im-
munohistochemical staining for Ki-67 and PCNA.
With regard to PCNA staining in particular, some
significance for PCNA staining (either as a diagnos-
tic or as a prognostic tool) has been reported in
such disparate lesions as hepatocellular tumors,
epithelial-myoepithelial carcinoma of salivary
gland origin, mast cell disease, endometrial adeno-
carcinoma, renal carcinoma, synovial sarcoma, and
dysplastic bronchial epithelium.47-54
As was the case with p53 immunostaining, ques-
tions have arisen with regard to the specificity of the
various antibody preparations available for identify-
ing PCNA, as well as the potentially confounding
influences that may be provided by such factors as
type and length of fixation employed and other tech-
nical variables.55-63 In general, PCNA labeling
increases as the mitotic count within the tissue sec-
tion increases .6’ This was seen in our series of small
cell tumors of bone as well. Separate groups of
lesions (distinct, that is, from groups that might have
been delineated based on mitotic activity alone)
were not distinguished by PCNA staining results.
The present study did not demonstrate any corre-
lation between nuclear p53 protein accumulation as
detected by immunostaining and tumor type, and so
it is unlikely that p53 positivity will prove to be of
great use in the differential diagnosis of these lesions.
A correlation between p53 positivity and PCNA stain-
ing or mitotic activity was likewise not apparent.
While follow-up data on our material is limited, the
rare p53 positive tumors did not appear to exhibit an
unusually aggressive or unusually indolent course
when compared with the p53 negative lesions.
Among the avenues open for future exploration
is the relationship of the protein product of the
murine double minute-2 gene (MDM2 gene located
on the long arm of chromosome 12) to p53 gene
mutation. Some have suggested that MDM2
amplification may inactivate the same regulatory
pathway as does p53 mutation. It appears that
these two mechanisms may act, at least in mes-
enchymal tumors, exclusively of one another, that
is, preliminary findings suggest that a given sar-
coma may exhibit either p53 mutation or MDM2
amplification but usually not both.65-67 It has been
suggested that those infrequent sarcomas exhibit-
ing both p53 mutation and MDM2 amplification
may follow a more aggressive course than those
harboring only one of these abnormalities.66
Confirmation of these observations promises to
yield further insights into the genesis and progres-
sion of tumors of mesenchymal tissues.
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